US FDA asks firms to check quality of glass drug vials
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has expressed concern over several recent incidents of injectable drugs, filled in small-volume glass vials, being recalled due to the formation of glass lamellae (ie glass fragments). The agency is asking manufacturers of these products to re-examine their supplier quality management programme with glass vial manufacturers to prevent such incidents1.